Simple Antibody Modification Boosts ADC Efficacy Against Poorly-Internalizing or Poorly-Expressing Cancer Cell Targets

摘要

An innovative antibody engineering technology (ADED) enhances ADC efficacy against both a poorly expressed receptor target and a poorly internalizing receptor target in cancer xenograft model. Strong in vivo efficacy data suggest that ADED can be adopted to unlock many traditionally challenging receptor targets for ADC development.